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ABSTRACT 
Objective: This study aims to synthesize acetylsalicylic acid (ASA) cocrystals using valine as a coformer via a co-crystallization technique to 
increase the solubility and dissolution rate of ASA. 
Methods: The ASA-valine cocrystal (1:1 molar ratio) was prepared using the solvent evaporation technique with ethanol: water (50:50). The 
cocrystal was characterized using Fourier transform infrared spectroscopy (FT-IR), Differential scanning calorimetry (DSC), Powder X-ray 
diffraction (PXRD), Scanning electron microscopy (SEM), melting point to confirm the formation of cocrystal. The evaluation of cocrystal was done 
by drug content determination, solubility and dissolution studies.  
Results: The prepared cocrystal was successfully confirmed for the formation of a hydrogen bond. The melting point of prepared cocrystal was 
decreased compared to pure ASA and valine, which indicated the formation of a new crystalline form. The FT-IR studies showed the formation of a 
new hydrogen bond by shifting the-O-H,-C=O and-N-H functional groups. SEM studies ensured that the prepared cocrystals were in needle-like 
appearance. Finally, DSC and PXRD studies were also indicated the successful formation of ASA-valine cocrystal. The drug release of cocrystal was 
found to be 100% at 60th min. Where in the case of pure ASA and marketed product of ASA exhibited the dissolution rate of 59% and 69% at 60th
Conclusion: The co-crystallization technique can be adopted as the best strategy to increase the solubility and dissolution rate of BCS class 2 drugs. 
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INTRODUCTION 
The significant thrust prompted by new technological advancements 
in pharmaceutical industries is to improve the fundamental 
properties of an API, such as solubility, flow properties, 
bioavailability, and physical and chemical stability [1]. As per the 
reports, nearly 40% of drugs are available in the market, and almost 
90% of drugs still in the developmental pipeline are facing solubility 
issues [2]. The poor aqueous solubility of pure drugs is one of the 
vital issues encountered while developing the pharmaceutical 
formulations administered through oral and transdermal routes [3, 
4]. The bioavailability of drugs that are administered orally be 
resultant by aqueous solubility and dissolution rate; thus, poor 
aqueous solubility can be the stepping stone of inadequate and 
variable absorption of these drugs making the absorption process 
solely dependent on aqueous solubility [5, 6]. Thus, to overcome the 
solubility issue of poorly aqueous soluble drugs, new solid-state 
forms of old drugs utilizing a variety of solubility enhancement 
techniques such as salification, cocrystallization, etc. are being 
looked into, which modifies the physicochemical properties of a 
drug without changing its pharmacological activity [7-9]. 
Since the physicochemical properties are often dependent on the 
crystal structure of drugs, many have reported that the crystal 
engineering of drugs helps overcome issues related to solubility and 
thermodynamic stability [10, 11]. The synthesis of cocrystal is one of 
the significant strategies to improve the physicochemical 
parameters of pure drug. From the past 15 y, research towards 
pharmaceutical cocrystals has doubled. They have gained 
tremendous ability to modify not only ionizable drugs like salts but 
also non-ionizable drugs or weakly ionizable drugs [12-16]. 
Cocrystals are solid crystalline materials comprised of two or more 
distinct molecular components. They cannot be distinguished as 
either solvates/hydrates or simple salts since they are 
interconnected via non-ionic interactions such as van der Waals 
interactions, hydrogen bonding and π-π stacking instead of ionic 
interactions. Thus, cocrystals are unique, where the proton transfer 
is unconditionally absent [17-24]. Hence, this area is in enormous 
expansion and significant over other solid-state modifications. The 
major dominance of cocrystals is the proficiency of modification of 
pure drug with refined solubility, dissolution rate, processability, 
thermal and hydration stability. Along with all the above-mentioned 
benefits, it is also possible to incorporate extra health benefits 
through the appropriate coformers. Although several properties of 
the pure drug are improved, the structure will not get al. tered, 
resulting in unchanged pharmacological activity [25-33].  
Aspirin is an acetyl derivative of salicylic acid that belongs to a 
biopharmaceutical classification system (BCS) class 2 drug with an 
aqueous solubility less than 1 mg/ml at 73 °F. It possesses a broad 
count of various bioactivities such as anti-inflammatory, anti-
pyretic, it also involved in reducing the risk of heart attack by 
thinning the blood [34]. Besides, the Carlo patron has reported that 
aspirin took part in reducing the risk associated with colorectal 
cancer [35]. Recently, the combinations of aspirin-4,4-bipyridine 
[36], aspirin-theophylline [37], aspirin-4,4-butane, aspirin-
pyridinepoly-2-ene [38] were successfully formed stable cocrystals, 
but none of them have studied the dissolution behavior of aspirin. 
In this present work, we have used valine fig. 1 as a conformer in the 
synthesis of acetylsalicylic acid (ASA) cocrystals due to their 
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impeccable potentiality in the formation of a hydrogen bond 
between the pure ASA fig. 2. Further, crystal structure 
characterizations, intermolecular interactions, thermal behaviors 
and dissolution behaviors of cocrystals were investigated using FT-
IR, DSC, SEM, PXRD, solubility studies and in vitro dissolution 
studies. The main goal of this study is to not only synthesize 
cocrystals of ASA with improved solubility and dissolution rate but 
also to furnish new insight into the design of cocrystals using valine 
as conformers, which is believed to construct potential cocrystals by 
forming non-ionic interactions between pure drugs. 
 
 
Fig. 1: Structural formula of acetylsalicylic acid (ASA) 
 
 
Fig. 2: Structural formula of valine 
 
MATERIALS AND METHODS 
Materials 
Acetylsalicylic acid (Aspirin) was purchased from Vasa Scientific 
Company (Bangalore, India). Valine of analytical grade was 
purchased from Central Drug House Pvt. Ltd (Karnataka, India). 
Absolute ethanol was purchased from Vasa Scientific Company 
(Bangalore, India). All chemicals were used as received without any 
further purification. 
Preparation of cocrystals 
Acetylsalicylic acid (540 mg) and valine (351 mg) (1:1 molar ratio) 
were ground by using the high energy vibrational mill into a finely 
grounded state (CMTTI-200, Japan) for about 3-5 min, further 
transferred into a 25 ml glass beaker and added 20 ml of 50% 
ethanol-water mixture. The mixture was stirred until a clear 
solution was obtained. Thereafter, allowed to crystallize at room 
temperature by slow evaporation for 10 d. White coloured crystals 
were obtained at the end of the 10th
Drug content determination 
 d. 
ASA-valine cocrystal equivalent to 10 mg of pure ASA was taken 
separately into a 100 ml volumetric flask. The contents in the flask 
were dissolved in absolute ethanol. From the resultant solution 1 ml 
of solution taken and diluted to 10 ml of absolute ethanol. The 
absorbance of the resultant solution was recorded at 268 nm using 
UV-1700 double beam spectrophotometer (Shimadzu, Japan). The 
average of three readings was taken [39]. 
Melting point study 
Melting points of the pure ASA, valine and ASA-valine cocrystal were 
measured using a Digital Melting temperature apparatus (Secor, 
India). 
Fourier transform infrared spectroscopy 
The Fourier Transform Infrared Spectroscopy (FT-IR) spectral 
analysis was identified as an additional channel to manifest the 
development of cocrystals. The distinct and novel peaks in the FT-IR 
spectra of cocrystals were indicative of the formation of new 
intermolecular hydrogen bonding. FT-IR spectrums of cocrystals 
were recorded on a Perkin Elmer FT-IR spectrophotometer (USA) 
using the KBr pellet method in the spectral range 4000-500 cm-1 
with a resolution of 2 cm-1 
Scanning electron microscopy  
[40]. 
The surface characteristics and shape of the ASA-valine co-crystals 
were analyzed by Scanning Electron Microscopy (SEM) (Joel Jsm-
5600, Japan). The samples for scanning electron microscopy were 
prepared by gently spreading the co-crystals on a double adhesive 
tape, which is stuck to an aluminum stub. The samples were then 
imaged using a 20 kV electron beam [41]. 
Differential scanning calorimetry 
The Differential Scanning Calorimetry (DSC) analysis was conducted 
on a 2910 Modulated DSC V4.4E instrument (USA). The samples 
were weighed accurately (2 to 3 mg) and placed in hermetically 
sealed 40 ml aluminium crucibles, scanned from 25-300 °C at a 
heating rate of 10 °C/min under a dry nitrogen atmosphere [42]. 
Powder x-ray diffraction 
The Powder X-Ray Diffraction (PXRD) patterns were collected on a 
Shimadzu XRD-7000 X-ray diffractometer (Japan) maxima with 
Cu-Kα radiation (1.540 Å). The tube voltage and amperage were 
set at 20 kV and 35 mA, respectively. Each sample was scanned 
between 5 and 60° 2θ with a step size of 0.02°. Before performing 
the experiments, the instrument was calibrated using a silicon 
standard [43]. 
Solubility study 
The solubility of ASA-valine cocrystal was determined by adding 
excess amounts of cocrystals in a Schott Duran bottle containing 5 
ml of pH 4.5 acetate buffer solutions. The mixture was stirred 
continuously at 25±0.5 °C for 48 h to achieve equilibrium. The 
resultant solution was filtered using a whatman filter paper. The 
supernatant was then diluted to make sure that the solution 
concentration point falls on the standard curve. The filtrate was 
analyzed by UV-1700 double beam spectrophotometer (Shimadzu, 
Japan) at 268 nm after suitable dilution. The absorbance of the 
solution was taken as the solubility of the ASA in terms of 
concentration. 
In vitro dissolution study 
The dissolution test was carried out in a USP type 1 apparatus 
(Basket method). The samples were placed in size 00 hard gelatin 
capsules. 900 ml of pH 4.5 acetate buffer was used as dissolution 
media at 37±0.5 °C temperature and maintaining the stirring speed 
at 50 rpm. The samples were drawn at the interval of 5, 10, 15, 20, 
25, 30, 45, 60, 90, and 120 min. Further fresh volume of the 
dissolution medium was replaced with the withdrawn volume to 
maintain the sink conditions. Samples withdrawn were analyzed at 
wavelength 268 nm using UV-1700 double beam spectrophotometer 
(Shimadzu, Japan) for determining the percentage of cumulative 
drug release [44]. 
RESULTS AND DISCUSSION 
Drug content determination 
The drug content in the prepared ASA-Valine cocrystal was found 
to be 95.3%. Since some of the product was retained in the beaker 
and could not able to remove completely, the percentage of drug 
content was not able to achieve 100%. This estimate of drug 
content will help in determining the concentration of cocrystals to 
be taken for dissolution studies to compare with pure ASA and 
marketed ASA. 
Melting point study 
The melting point is determined to study the thermal behaviour of 
the prepared cocrystals. The melting point of the prepared cocrystal 
was found to be 126 °C shown in table 1, which is in between the 
melting point of pure ASA and valine. Thus this confirms the 
formation of a new crystalline form other than ASA and valine. 
Fourier transform infrared spectroscopy 
Cocrystal formation in the present study was initially confirmed by 
comparing the IR stretching frequencies of various functional groups 
present in cocrystal with pure ASA [45]. Technically no shift in the 
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carbonyl stretching frequency was observed for ASA-valine 
cocrystal. This indicated the carbonyl groups in both ASA and valine 
remain untouched. A considerable shift in amine/hydroxyl 
stretching frequency was observed for ASA-valine cocrystal, which 
confirms the formation of a hydrogen bond between ASA and valine. 
The detailed stretching frequency of ASA and the prepared 
cocrystals are shown in table 2. The FT-IR spectra of pure ASA and 
ASA-valine cocrystal are shown in fig. 3, 4. 
 
Table 1: Melting point of pure ASA, valine and ASA-valine cocrystal 
S. No. Sample Mean melting point ( °C)±SD 
1 ASA 133±04 
2 Valine 294±02 
3 ASA-valine cocrystal 127±04 
*All values are expressed as mean±SD, (n=3). 
 
Table 2: FT-IR stretching frequencies of ASA and ASA-valine cocrystals 
S. No. Type of band ASA (cm-1 ASA-valine cocrystal (cm) -1) 
1 -O-H (st) 3430 (s) 3466 (vs) 
2 -C=O (st) 1594 (vs) 1594 (vs) 
3 -N-H (st) - 3255 (m) 
*(vs):-very strong; (s):-strong; (m):-medium; (st):-stretching. 
 
 
Fig. 3: FT-IR spectra of pure ASA 
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Scanning electron microscopy  
The surface morphology and appearance of the ASA-valine cocrystal 
was examined by SEM. As observed from the SEM images, the 
crystals were in needle-like appearance. The image of ASA-valine 
was shown in fig. 5. 
Differential scanning calorimetry 
DSC analysis of the synthesized cocrystals was performed to 
determine the exact melting temperature and to correlate the 
melting temperature with crystal density and intermolecular 
interactions. It is known that the melting temperature of the 
cocrystal often falls between the melting temperature of starting 
materials or below the starting material melting point [46]. In the 
present work, the ASA-valine cocrystal was found to melt exactly in 
between the melting temperature of pure ASA and valine as shown 
in fig. 6. At the temperature range of 120 °C, the decomposition of 
ASA-valine was observed, which corresponds to the mass change of 
57% that assigned the separation of valine from ASA due to the 
breakage of a hydrogen bond between ASA-valine cocrystal. 
 
 
Fig. 5: SEM observation of ASA-valine cocrystal 
 
 
Fig. 6: DSC thermogram of ASA-valine cocrystal 
 
Powder x-ray diffraction 
PXRD is a reliable technique to characterize the formation of a new 
crystalline phase in solid-state. A different PXRD pattern of the 
product after cocrystallization experiments from the individual 
components confirms the formation of a new crystalline phase 
[47]. The PXRD patterns for ASA and ASA-valine cocrystal are 
shown in fig. 7, 8. ASA exhibited characteristic crystalline peaks at 
2θ values of 11°, 16°, 18°, 23.5°, 29.5°, 31.5°, 32.5° and 40°, 
whereas ASA-valine cocrystal exhibited characteristic crystalline 
peaks at 2θ values of 10.5°, 17.5°, 28°, 32° and 36°. The different 
peaks in the cocrystal’s PXRD pattern could imply the existence of 
interactions between ASA and valine to form a new cocrystalline 
phase. 
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Fig. 7: PXRD pattern of pure ASA 
 
 
Fig. 8: PXRD pattern of ASA-valine cocrystal 
 
Solubility study 
The solubility of ASA-valine cocrystal was performed in a pH 4.5 acetate 
buffer solution. The pure ASA exhibited a solubility of 3 mg/ml. The ASA-
valine cocrystal was showed an increased solubility of 17 mg/ml 
compared to pure ASA. This is due to the formation of a hydrogen bond 
between ASA and valine. Due to the presence of a hydrophilic chain in 
the cocrystal, solubility has increased to a greater extent. 
In vitro dissolution study 
The in vitro drug release study of ASA-valine by USP type 1 
apparatus (Basket method). The cocrystal was placed in a size 00 
hard gelatin capsule. The dissolution media was filled with 900 ml of 
pH 4.5 acetate buffer solution maintained at temperature 37±0.5 °C 
with a stirring speed of 50 rpm. The samples were drawn at the 
interval of 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 min. The drug 
release of ASA-valine cocrystal was found to be 100% at 60th min. 
Where in the case of pure ASA and marketed product of ASA 
exhibited the dissolution rate of 59% and 69% at 60th
 
 min, 
respectively. The increase in dissolution rate of ASA-valine co-
crystal may be due to strong intermolecular hydrogen bonding 
between ASA and valine. This is due to the presence of free 
carboxylic acid and amine functional groups in the valine. 
Nevertheless, the hydrophilic group present in the valine is 
responsible for the formation of hydrophilic ends in the ASA-valine 
co-crystals. Thus, the ASA-valine cocrystal showed a 1.7 and 1.44 
folds increase in dissolution rate compared to pure ASA and 
marketed product of ASA, respectively as shown in fig. 9. 
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Fig. 9: Dissolution graph of pure ASA, marketed ASA and ASA-valine cocrystal, *
 
All values are expressed as mean±SD, (n=3) 
CONCLUSION 
Co-crystallization technique can be an efficient technique for 
enhancement of the solubility and dissolution rate of BCS class 2 
drugs. In this study, a novel cocrystal of ASA-valine was synthesized 
using the solvent evaporation technique and characterized. The 
melting of the prepared cocrystal remained lesser than the pure 
ASA, thus confirming the formation of a new crystalline form. The 
FT-IR, DSC and PXRD studies revealed the successful formation of 
cocrystals. The surface morphology by using SEM revealed the 
formation of needle-like crystals. The dissolution studies exhibited 
an increased dissolution rate compared to pure ASA and marketed 
ASA. Thus the ASA-valine cocrystal can be a greater alternative for 
increased solubility and dissolution rate compared to pure ASA. 
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